ESMO 2021 | ALTA-1L: final overall survival results of brigatinib vs crizotinib for ALK+ lung cancer

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the overall survival results from the ALTA-1L trial (NCT02737501), which compared brigatinib to crizotinib as a first-line therapy for patients with ALK+ lung cancer. The median progression-free survival of brigatinib was 24 months, compared to 11 months for crizotinib, as assessed by a Blinded Independent Review Committee (BIRC). Crossover was built into the study, with 47% of patients receiving crizotinib switching over to brigatinib. Dr Popat highlights the potency of brigatinib in a post-crizotinib setting. The 4-year survival for patients treated with brigatinib was 66% compared to 60% for crizotinib. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.